Piper Sandler Calls Neogenomics (NEO) a 'Compelling, Contrarian Investment Opportunity'
Tweet Send to a Friend
Piper Sandler analyst David Westenberg reiterated an Overweight rating and $11.00 price target on Neogenomics (NASDAQ: NEO).The analyst commented: "NeoGenomics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
